NFKB1 and fatty liver disease: It has been demonstrated that rosiglitazone treatment improves high-fat- and high-sucrose-induced hepatic steatosis and inflammation in rats [44], suppresses skeletal muscle inflammation by blocking the NF-κB pathway in OLETF rats [45], and inhibits chronic pancreatitis-induced activation of the hepatic IKK-β/NF-κB pathway in rats [6].